Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic
  • Search Hotels in Sausalito

  • ROOMS:

Dr. Lynn Kirkpatrick, Featured Speaker to Discuss Ensysce Overdose Protection Platform at DCAT Seminar

~ Ensysce Biosciences and Quotient Sciences Showcase a Unique Collaboration ~

SAN DIEGO, CA / ACCESSWIRE / March 6, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced Dr. Lynn Kirkpatrick, Chief Executive Officer, is a featured speaker at a lunch seminar on March 22, 2023 in New York sponsored by partner Quotient Sciences. The Seminar "Strategies for Achieving Regulatory Milestones Faster: An Ensysce Biosciences & Quotient Sciences customer case study demonstrating the benefits of an integrated approach for accelerating development" is taking place in tandem with Drug, Chemical & Associated Technologies Association (DCAT) Week. Dr. Kirkpatrick will be discussing how Ensysce's collaboration with Quotient has helped progress the Company's unique programs to combat opioid abuse and misuse, and highlight its overdose protection platform, MPARTM (Multi-Pill Abuse Resistance).

Ensysce selected Quotient as a partner because of their integrated Translational Pharmaceutics® program, a drug development and manufacturing accelerator. Translational Pharmaceutics allows the manufacture and clinical evaluation of a drug product in real time. This real time evaluation has allowed Ensysce to advance its overdose protection program with PF614-MPARTM faster than could be achieved using traditional manufacturing processes.

"Our partnership with Quotient Sciences is an exceptional case study for Translational Pharmaceutics®, and we are excited to highlight how it has facilitated the progress of our clinical development of PF614-MPARTM," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences. "PF614-MPAR™ is potentially a first-in-class agent designed to treat severe pain while delivering overdose protection. This ‘Next Generation' opioid integrates both abuse deterrence and overdose protection in one product which could ultimately enhance and save many lives. We look forward to sharing updates on the program with seminar attendees."

Translational Pharmaceutics Seminar

Date: Thursday, March 22, 2023

Location: Smith & Wollensky's Steakhouse, New York

Time: 11:30 am - 1:30 pm ET

About Ensysce Biosciences

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a unique, tamper-proof treatment option for pain that minimizes the risk of both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit

About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. For more information visit

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:
MZ Group North America
Shannon Devine

SOURCE: Ensysce Biosciences, Inc.

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.